PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.

Trial Profile

PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Thrombosis
  • Focus Therapeutic Use
  • Acronyms TE-Prove
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2011 Additional locations (Belgium, England, France, Hungary, Ireland, Italy, Poland, Spain) added as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top